Viread Pediatric Trials May Proceed Despite Bone Toxicity Potential - FDA
Executive Summary
Gilead's Viread pediatric studies should proceed despite a potential risk of bone toxicity, FDA told the Antiviral Drugs Advisory Committee during its Oct. 3 review of the HIV treatment.
You may also be interested in...
FDA May Limit Requests For Antiretroviral Drug Studies In Neonates
FDA is considering limiting its requests for antiretroviral drug studies in HIV-infected and HIV-exposed neonates
FDA May Limit Requests For Antiretroviral Drug Studies In Neonates
FDA is considering limiting its requests for antiretroviral drug studies in HIV-infected and HIV-exposed neonates
Gilead Viread Virology Data Will Distinguish HIV Drug In Physician Promotions
Gilead will highlight Viread virology data to distinguish the HIV treatment in physician promotions